Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.7424
+0.0064 (0.87%)
At close: Apr 17, 2026, 4:00 PM EDT
0.7276
-0.0148 (-1.99%)
After-hours: Apr 17, 2026, 6:38 PM EDT
Pasithea Therapeutics Employees
Pasithea Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,085,537
Market Cap
18.52M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2024 | 4 | -4 | -50.00% | 4 | 0 |
| Dec 31, 2023 | 8 | -7 | -46.67% | 8 | 0 |
| Dec 31, 2022 | 15 | 10 | 200.00% | 15 | 0 |
| Dec 31, 2021 | 5 | 2 | 66.67% | 3 | 2 |
| Jun 30, 2021 | 3 | - | - | 1 | 2 |
| Mar 31, 2021 | 3 | - | - | 1 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| Quantum BioPharma | 17 |
| SeaStar Medical Holding | 17 |
| Lipocine | 14 |
| VYNE Therapeutics | 10 |
| Genenta Science | 9 |
| Allarity Therapeutics | 8 |
| Traws Pharma | 7 |
KTTA News
- 18 days ago - Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - GlobeNewsWire